All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On the 2nd of October 2019, the European Patent Office has issued a Notice of Allowance for EU Patent for the use of cannabidiol (CBD, a non-psychoactive component of cannabis with immunosuppressive properties) for the prevention and treatment of acute graft-versus-host disease (aGvHD).1 There are currently no approved therapies for the prevention and very few licensed drugs for the treatment of aGvHD. Therefore, the development of efficient therapies to prevent and treat aGvHD is a major goal of allogeneic bone marrow transplantation.2
The company has stated that the new, proprietary CBD product which is an oral formulation in olive oil, that was designed to overcome previous issues of poor oral bioavailability and stability, has the potential to be used as a treatment option for bone marrow transplant recipients who are at high risk of developing aGvHD.1 CBD has previously been granted orphan drug designation by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and the results for the phase II study (NCT03840512) were previously covered by the GvHD hub.
Subscribe to get the best content related to GvHD delivered to your inbox